DNA Damage-Response Defects in Prostate Cancer Risk
DNA Damage-Response Defects in Prostate Cancer Risk
批准号:
7502688
负责人:
WANGUO LIU
金额:
$31.24万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-09-29 至 2011-07-31
关键词:
AgeAllelesApoptosisAreaBRCA1 geneBiopsyBloodCHEK2 geneCancer FamilyCancer PatientCandidate Disease GeneCase-Control StudiesClassificationComplexConsultControl GroupsCountryDNADNA DamageDataDatabasesDefectDigital Rectal ExaminationDiseaseDisruptionEtiologyFamilyFamily history ofFrameshift MutationFrequenciesGenesGeneticGenetic Predisposition to DiseaseGenetic RiskGenome StabilityGenotypeGerm-Line MutationGoalsHereditary DiseaseHigh Pressure Liquid ChromatographyHumanImageLeukocytesMalignant NeoplasmsMalignant neoplasm of prostateMeasurementMethodsMutateMutationNeoplastic Cell TransformationNumbersPathway interactionsPenetrancePhosphotransferasesPlayPopulationPredispositionPreventionPrevention strategyProteinsRaceReportingResearch PersonnelRiskRisk FactorsRisk MarkerRoleSamplingScreening for Prostate CancerTP53 geneTechnologyTestingTimeUniversitiesVariantbasecancer riskcase controlclinically significantgenetic linkage analysisgenetic risk factorgenetic variantimprovedinsightmalemenmutantmutation carriernovelperipheral bloodprogramsresponseserum PSAsuccesstooltumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): There is substantial evidence that genetics plays an important role in the etiology of prostate cancer. However, the genetic basis underlying this disease remains poorly understood. It is becoming more apparent that genetic variants in a number of low-penetrance alleles of multiple genes may contribute to prostate cancer risk. Additionally, a growing body of evidence suggests that disruption of the DNA damage-response pathway confer susceptibility to prostate cancer. Indeed, we have demonstrated that germline mutations in CHK2 and p53AIP1 diminish their capacities to respond to DNA damage and increased prostate cancer risk, but more comprehensive and systematic studies are needed. In this study, we propose to systematically test the hypothesis that rare or common genetic variants in the DNA damage-response pathway genes, either individually or in combination, are risk factors for prostate cancer. In Aim 1, we will screen 56 well-documented DNA damage-response genes for non-synonymous variants in blood DNA from 94 prostate cancer patients and 94 unaffected men. In Aim 2, we will test the significance of these variants in a case-control study that uses two sets of previously identified cases - those with a strong family history of prostate cancer (n=498 from 189 families) and those with a reported negative prostate cancer family history (n=499), and a population-based control group (n=558). The controls have been extensively screened for prostate cancer by digital rectal examination, serum PSA measurement, transrectal sonographic imaging, and when indicated, by biopsy. In Aim 3, we will validate the variants in Aim 2 that are associated with either familial or sporadic prostate cancer in an independent sets of cases and controls including 734 familial cases, 462 sporadic cases, and 500 age- matched unaffected control men collected at Johns Hopkins University. At the conclusion of this project, we will have provided important insights into the potential role of a group of genes important in DNA damage-response and generated hypotheses as to how these genes interact with each other in the etiology of prostate cancer. Additionally, by making pairwise comparisons among these three groups of subjects, we will be able to discern whether these genetic variants are more strongly associated with familial or sporadic prostate cancer, similarly associated with both or with neither. The ultimate goal of this project is to identify genetic risk factors of prostate cancer in order to improve our understanding of the etiology of this disease and to provide tools for potential identification of men at increased risk of developing the disease in whom prevention strategies might be targeted.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ARD1-dependent Androgen Receptor Signaling in Prostate Cancer
-
批准号:8808251
-
项目类别:
-
资助金额:$19.05万
-
财政年份:2015
-
负责人:WANGUO LIU
-
依托单位:
Germline Mutations in African American Families with Aggressive Prostate Cancer
-
批准号:8877077
-
项目类别:
-
资助金额:$19.05万
-
财政年份:2015
-
负责人:WANGUO LIU
-
依托单位:
DNA Damage-Response Defects in Prostate Cancer Risk
-
批准号:7931198
-
项目类别:
-
资助金额:$20.29万
-
财政年份:2009
-
负责人:WANGUO LIU
-
依托单位:
DNA Damage-Response Defects in Prostate Cancer Risk
-
批准号:7905867
-
项目类别:
-
资助金额:$29.46万
-
财政年份:2007
-
负责人:WANGUO LIU
-
依托单位:
DNA Damage-Response Defects in Prostate Cancer Risk
-
批准号:7847020
-
项目类别:
-
资助金额:$1.66万
-
财政年份:2007
-
负责人:WANGUO LIU
-
依托单位:
DNA Damage-Response Defects in Prostate Cancer Risk
-
批准号:7265054
-
项目类别:
-
资助金额:$31.39万
-
财政年份:2007
-
负责人:WANGUO LIU
-
依托单位:
DNA Damage-Response Defects in Prostate Cancer Risk
-
批准号:7679439
-
项目类别:
-
资助金额:$32.08万
-
财政年份:2007
-
负责人:WANGUO LIU
-
依托单位:
海外基金